Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00580216 · ClinicalTrials.gov registry record · Phase 3
Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 3,773
- Enrollment target
NCT00580216: Clinical Trial Phase 3 study, sponsored by Sanofi.
NCT00580216 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 3,773 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (389% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00580216, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 3,773 participants
- Enrollment target
Study Summary
The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio (INR) adjusted-dose warfarin in patients with atrial fibrillation (AF).
Interventions
- DRUG Warfarin
- DRUG Idrabiotaparinux sodium
- DRUG Avidin
- DRUG Placebo (for warfarin)
- DRUG Placebo (for idrabiotaparinux)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,773 participants |
| Start Date | 2007-12 |
| Est. Completion | 2010-10 |
| Phase | Phase 3 |
Why NCT00580216 stopped before completion
NCT00580216 is an interventional study that assigns participants to a tested intervention. Its 3,773 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (389% higher).
The record links to 0 conditions, and to 5 interventions - of which Warfarin is the first listed.
NCT00580216 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00580216 about?
NCT00580216 is a clinical study titled "Evaluation of Weekly Idrabiotaparinux Sodium Versus Oral Adjusted-dose Warfarin to Prevent Stroke and Systemic Thromboembolic Events in Patients With Atrial Fibrillation". The objective is to evaluate whether once weekly subcutaneous (SC) injection of idrabiotaparinux sodium (biotinylated idraparinux) is at least as efficient to prevent clots in brain and in the other organs than oral international normalized ratio (INR) adjusted-dose warfarin in patients with atrial ...
What is the current status of trial NCT00580216?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 3,773 participants. The study started on 2007-12. Estimated completion is 2010-10.
What interventions are being tested in trial NCT00580216?
The interventions under investigation include: Warfarin (DRUG), Idrabiotaparinux sodium (DRUG), Avidin (DRUG), Placebo (for warfarin) (DRUG), Placebo (for idrabiotaparinux) (DRUG).
Who is sponsoring clinical trial NCT00580216?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00580216's enrollment target sits among peer trials
3,773 66th of 2000 higher than 1,935 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04573660 · 3,784 participants
Abbott Vascular Medical Device Registry
- NCT06172660 · 3,750 participants
Real-World Effectiveness of Perinatal RSV Immunoprophylaxis
- NCT06298253 · 3,750 participants · NA
Behavioral Economics to Implement a Traffic Light Nutrition Ranking System: Study 2
- NCT06076304 · 3,720 participants · Phase 4
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Acute Sinusitis
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia